Cosunter(SZ:300436) Xin Lang Cai Jing·2026-01-28 02:59Group 1 - Guangshentang's stock price increased by 5.66% to 97.32 CNY per share, with a trading volume of 467 million CNY and a turnover rate of 3.64%, resulting in a total market capitalization of 15.5 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among Guangshentang's top ten circulating shareholders, a fund under China Europe Fund reduced its holdings by 1.1365 million shares, now holding 708,100 shares, which represents 0.52% of the circulating shares, with an estimated floating profit of approximately 3.6895 million CNY [2] - The China Europe Medical Health Mixed Fund A (003095) has a total asset size of 13.843 billion CNY and has achieved a year-to-date return of 2.06%, ranking 6843 out of 8864 in its category [2] Group 3 - The fund manager of China Europe Medical Health Mixed Fund A is Ge Lan, who has been in the position for 11 years and 3 days, with a total asset size of 35.389 billion CNY and a best return of 101.04% during her tenure [3] - Zhao Lei, the other fund manager, has been in the position for 209 days, managing assets of 26.943 billion CNY, with a best return of 4.55% during his tenure [3]